Current treatment of early breast cancer: Adjuvant and neoadjuvant therapy

F1000Research

Volumn 3, Issue , 2014, Pages

  Lim, Bora ^c   Miller, Elizabeth ^a   Lee, Hee Jin ^b   Lulla, Amriti ^c   Hernandez, Liz ^c   Gokare, Prashanth ^c  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b University of Ulsan College of Medicine   (South Korea)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; EVEROLIMUS; FILGRASTIM; FLUOROURACIL; LAPATINIB; LETROZOLE; MELPHALAN; METHOTREXATE; PACLITAXEL; PERTUZUMAB; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; VELIPARIB; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ARTICLE; BILATERAL CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DOSAGE SCHEDULE COMPARISON; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY CANCER; HUMAN; HYPERCALCEMIA; LYMPH NODE METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OSTEOPOROSIS; OVERALL SURVIVAL; POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

EID: 84923197584     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.4340.1     Document Type: Article

References (115)

1. IARC GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012.2012. Reference Source
2. Bilal E Dutkowski J Guinney J: Improving breast cancer survival analysis through competition-based multidimensional modeling. PLOS Comput Biol. 2013;9(5):e1003047. 23671412 10.1371/journal.pcbi.1003047 3649990
3. Lehmann BD Bauer JA Chen X: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-2767. 21633166 10.1172/JCI45014 3127435
4. Voduc KD Cheang MC Tyldesley S: Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28(10):1684-1691. 20194857 10.1200/JCO.2009.24.9284
5. van de Vijver MJ He YD van't Veer LJ: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999-2009. 12490681 10.1056/NEJMoa021967
6. van't Veer LJ Dai H van de Vijver MJ: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530-536. 11823860 10.1038/415530a
7. Carlson RW Hudis CA Pritchard KI: Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. J Natl Compr Canc Netw. 2006;4(10):971-979. 17112447
8. Stanford JL Szklo M Brinton LA: Estrogen receptors and breast cancer. Epidemiol Rev. 1986;8:42-59. 3533584
9. Goldhirsch A Wood WC Coates AS: Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736-1747. 21709140 10.1093/annonc/mdr304 3144634
10. Bergh J Jonsson PE Glimelius B: A systematic overview of chemotherapy effects in breast cancer. Acta Oncol. 2001;40(2-3):253-281. 11441936 10.1080/02841860120784
11. Bonadonna G Moliterni A Zambetti M: 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ. 2005;330(7485):217. 15649903 10.1136/bmj.38314.622095.8F 546063
12. Group EBCTC. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717. 15894097 10.1016/S0140-6736(05)66544-0
13. Peto R Davies C Godwin J: Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432-444. 22152853 10.1016/S0140-6736(11)61625-5 3273723
14. Jatoi I Hilsenbeck SG Clark GM: Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol. 1999;17(8):2334-2340. 10561295
15. Bonadonna G Brusamolino E Valagussa P: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976;294(8):405-410. 1246307 10.1056/NEJM197602192940801
16. Palmieri C Jones A: The 2011 EBCTCG polychemotherapy overview. Lancet. 2012;379(9814):390-392. 22152852 10.1016/S0140-6736(11)61823-0
17. Fisher B Redmond C Wickerham DL: Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol. 1989;7(5):572-582. 2651576
18. Fisher B Brown AM Dimitrov NV: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990;8(9):1483-1496. 2202791
19. Fisher B Anderson S Tan-Chiu E: Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol. 2001;19(4):931-942. 11181655
20. Dignam JJ Huang L Ries L: Estimating breast cancer-specific and other-cause mortality in clinical trial and population-based cancer registry cohorts. Cancer. 2009;115(22):5272-5283. 19670456 10.1002/cncr.24617 2783951
21. Muss HB Berry DA Cirrincione CT: Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009;360(20):2055-2065. 19439741 10.1056/NEJMoa0810266 3082436
22. Francis P Crown J Di Leo A: Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst. 2008;100(2):121-133. 18182617 10.1093/jnci/djm287
23. Mackey JR Martin M Pienkowski T: Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013;14(1):72-80. 23246022 10.1016/S1470-2045(12)70525-9
24. Henderson IC Berry DA Demetri GD: Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21(6):976-983. 12637460 10.1200/JCO.2003.02.063
25. Mamounas EP Bryant J Lembersky B: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23(16):3686-3696. 15897552 10.1200/JCO.2005.10.517
26. Citron ML Berry DA Cirrincione C: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431-1439. 12668651 10.1200/JCO.2003.09.081
27. Budd GT Barlow WE Moore HCF: First analysis of SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early breast cancer. -- Budd et al.29 (15): 1004 -- ASCO Meeting Abstracts. J Clin Oncol. 2011;29(15_suppl):s1004. Reference Source
28. Martin M Ruiz A Ruiz Borrego M: Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study. J Clin Oncol. 2013;31(20):2593-2599. 23733779 10.1200/JCO.2012.46.9841
29. Dutertre M Smith CL: Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther. 2000;295(2):431-437. 11046073
30. Trunet PF Vreeland F Royce C: Clinical use of aromatase inhibitors in the treatment of advanced breast cancer. J Steroid Biochem Mol Biol. 1997;61(3-6):241-245. 9365196
31. Jordan VC: Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2(3):205-213. 12612646 10.1038/nrd1031
32. Waters EA Cronin KA Graubard BI: Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev. 2010;19(2):443-6. 20142242 10.1158/1055-9965.EPI-09-0930 3038785
33. Davies C Pan H Godwin J: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805-816. 23219286 10.1016/S0140-6736(12)61963-1 3596060
34. Howell A Cuzick J Baum M: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60-62. 15639680 10.1016/S0140-6736(04)17666-6
35. Goss PE Ingle JN Pater JL: Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol. 2008;26(12):1948-1955. 18332475 10.1200/JCO.2007.11.6798
36. Mouridsen H Giobbie-Hurder A Goldhirsch A: Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361(8):766-776. 19692688 10.1056/NEJMoa0810818 2921823
37. Dowsett M Cuzick J Ingle J: Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509-518. 19949017 10.1200/JCO.2009.23.1274
38. Chao C Studts JL Abell T: Adjuvant chemotherapy for breast cancer: how presentation of recurrence risk influences decision-making. J Clin Oncol. 2003;21(23):4299-4305. 14581440 10.1200/JCO.2003.06.025
39. Welcome to Adjuvant! Online. In.2014.
40. Ravdin PM Siminoff LA Davis GJ: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001;19(4):980-991. 11181660
41. Fisher B Dignam J Tan-Chiu E: Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst. 2001;93(2):112-20. 11208880 10.1093/jnci/93.2.112
42. Dowsett M Cuzick J Wale C: Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28(11):1829-1834. 20212256 10.1200/JCO.2009.24.4798
43. Paik S Tang G Shak S: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-34. 16720680 10.1200/JCO.2005.04.7985
44. Institute NC. The TAILORx Breast Cancer Trial - National Cancer Institute.2010. Reference Source
45. Albain KS Barlow WE Shak S: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55-65. 20005174 10.1016/S1470-2045(09)70314-6 3058239
46. Gonzalez-Angulo A Barlow E Gralow J: SWOG S1007: A phase III randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less. 2011 ASCO annual meeting: suppl: abstr TPS104. J Clin Oncol. 2013;29. Reference Source
47. Bastien RR Rodriguez-Lescure A Ebbert MT: PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics. 2012;5:44. 23035882 10.1186/1755-8794-5-44 3487945
48. Dowsett M Sestak I Lopez-Knowles E: Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013;31(22):2783-90. 23816962 10.1200/JCO.2012.46.1558
49. Agendia. MammaPrint - MammaPrint - everything you need to know about MammaPrint. In.2014.
50. Schramek D Leibbrandt A Sigl V: Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010;468(7320):98-102. 20881962 10.1038/nature09387 3084017
51. Robert E Coleman H Cameron D: Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2014;365(15):1396-1405. 21995387 10.1056/NEJMoa1105195
52. Paterson AH Anderson SJ Lembersky BC: Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 2012;13(7):734-742. 22704583 10.1016/S1470-2045(12)70226-7
53. von Minckwitz G Untch M Blohmer JU: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796-1804. 22508812 10.1200/JCO.2011.38.8595
54. von Minckwitz GRM Eidtmann H Tesch H: The phase III NATAN study (GBC 36/ABCSG XX). In.2014.
55. Gregory W Marshall H Bell R: Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: results of a meta-analysis. J Clin Oncol. 2012;30. Reference Source
56. Yarden Y: Biology of HER2 and its importance in breast cancer. Oncology. 2001;61(Suppl 2):1-13. 11694782 10.1159/000055396
57. Yarden Y Shilo BZ: SnapShot: EGFR signaling pathway. Cell. 2007;131(5):1018. 18045542 10.1016/j.cell.2007.11.013
58. Vogel C Cobleigh MA Tripathy D: First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. A preliminary report. Eur J Cancer. 2001;37(Suppl 1):25-29. 11342197 10.1016/S0959-8049(00)00405-6
59. Barok M Isola J Palyi-Krekk Z: Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007;6(7):2065-2072. 17620435 10.1158/1535-7163.MCT-06-0766
60. Slamon D Eiermann W Robert N: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273-1283. 21991949 10.1056/NEJMoa0910383 3268553
61. Joensuu H Bono P Kataja V: Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009;27(34):5685-5692. 19884557 10.1200/JCO.2008.21.4577
62. Goldhirsch A Gelber RD Piccart-Gebhart MJ: 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013;382(9897):1021-1028. 23871490 10.1016/S0140-6736(13)61094-6
63. Perez EA Suman VJ Davidson NE: HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006;24(19):3032-3038. 16809727 10.1200/JCO.2005.03.4744
64. Spielmann M Roche H Delozier T: Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol. 2009;27(36):6129-6134. 19917839 10.1200/JCO.2009.23.0946
65. Hortobagyi GN Perez EA: Integration of trastuzumab into adjuvant systemic therapy of breast cancer: ongoing and planned clinical trials. Semin Oncol. 2001;28(5 Suppl 16):41-46. 11706395 10.1016/S0093-7754(01)90281-7
66. Piccart-Gebhart MJ Procter M Leyland-Jones B: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-1672. 16236737 10.1056/NEJMoa052306
67. Holbro T Beerli RR Maurer F: The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A. 2003;100(15):8933-8938. 12853564 10.1073/pnas.1537685100 166416
68. Rexer BN Arteaga CL: Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog. 2012;17(1):1-16. 22471661 10.1615/CritRevOncog.v17.i1.20 3394454
69. Huw LY O'Brien C Pandita A: Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer. Oncogenesis. 2013;2:e83. 24366379 10.1038/oncsis.2013.46 3940863
70. Loi S: Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. Oncoimmunology. 2013;2(7):e24720. 24073365 10.4161/onci.24720 3782009
71. Clynes RA Towers TL Presta LG: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6(4):443-446. 10742152 10.1038/74704
72. Zhang D Pal A Bornmann W: Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther. 2008;7(7):1846-50. 18644997 10.1158/1535-7163.MCT-08-0168 2525738
73. Johnston SR Leary A: Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc). 2006;42(7):441-453. 16894399 10.1358/dot.2006.42.7.985637
74. Goss PE Smith IE O'Shaughnessy J: Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(1):88-96. 23234763 10.1016/S1470-2045(12)70508-9
75. Metzger-Filho O Winer EP Krop I: Pertuzumab: optimizing HER2 blockade. Clin Cancer Res. 2013;19(20):5552-5556. 23942091 10.1158/1078-0432.CCR-13-0518
76. de Ruijter TC Veeck J de Hoon JP: Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 2011;137(2):183-192. 21069385 10.1007/s00432-010-0957-x 3018596
77. Hudis CA Gianni L: Triple-negative breast cancer: an unmet medical need. Oncologist. 2011;16(Suppl 1):1-11. 21278435 10.1634/theoncologist.2011-S1-01
78. Hudis CA Gianni L: Triple-negative breast cancer: an unmet medical need. Oncologist. 2011;16(Suppl 1):1-11. 21278435 10.1634/theoncologist.2011-S1-01
79. Clarke M Coates AS Darby SC: Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet. 2008;371(9606):29-40. 18177773 10.1016/S0140-6736(08)60069-0
80. Martin M Segui MA Anton A: Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med. 2010;363(23):2200-2210. 21121833 10.1056/NEJMoa0910320
81. Liedtke C Mazouni C Hess KR: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275-1281. 18250347 10.1200/JCO.2007.14.4147
82. Young SR Pilarski RT Donenberg T: The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer. 2009;9:86. 19298662 10.1186/1471-2407-9-86 2666759
83. Kwon JS Gutierrez-Barrera AM Young D: Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol. 2010;28(27):4214-4220. 20733129 10.1200/JCO.2010.28.0719
84. Linderholm B Hellborg H Johansson U: Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol. 2009;20(10):1639-1646. 19549711 10.1093/annonc/mdp062
85. Greenberg S Rugo HS: Triple-negative breast cancer: role of antiangiogenic agents. Cancer J. 2010;16(1):33-38. 20164688 10.1097/PPO.0b013e3181d38514
86. Cameron D Brown J Dent R: Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 2013;14(10):933-942. 23932548 10.1016/S1470-2045(13)70335-8
87. Deo SV Bhutani M Shukla NK: Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0). J Surg Oncol. 2003;84(4):192-197. 14756429 10.1002/jso.10323
88. Sweeting RS Klauber-Demore N Meyers MO: Young women with locally advanced breast cancer who achieve breast conservation after neoadjuvant chemotherapy have a low local recurrence rate. Am Surg. 2011;77(7):850-855. 21944346
89. Akay CL Meric-Bernstam F Hunt KK: Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol. 2012;19(3):901-907. 21861223 10.1245/s10434-011-2006-7
90. Matuschek C Bolke E Roth SL: Long-term outcome after neoadjuvant radiochemotherapy in locally advanced noninflammatory breast cancer and predictive factors for a pathologic complete remission: results of a multivariate analysis. Strahlenther Onkol. 2012;188(9):777-781. 22878547 10.1007/s00066-012-0162-8
91. Kaufmann M von Minckwitz G Mamounas EP: Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19(5):1508-1516. 22193884 10.1245/s10434-011-2108-2
92. van der Hage JA van de Velde CJ Julien JP: Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19(22):4224-4237. 11709566
93. Mauri D Pavlidis N Ioannidis JP: Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(3):188-194. 15687361 10.1093/jnci/dji021
94. Krainick-Strobel UE Lichtenegger W Wallwiener D: Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer. 2008;8:62. 18302747 10.1186/1471-2407-8-62 2270851
95. Thomas E Holmes FA Smith TL: The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol. 2004;22(12):2294-2302. 15197190 10.1200/JCO.2004.05.207
96. Cameron DA Anderson ED Levack P: Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy. Br J Cancer. 1997;76(8):1099-1105. 9376273 10.1038/bjc.1997.514 2228097
97. Cameron DA Anderson ED Levack P: Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy. Br J Cancer. 1997;76(8):1099-1105. 9376273 10.1038/bjc.1997.514 2228097
98. Semiglazov V Semiglazov V Ivanov V: The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER- positive breast cancer. J Clin Oncol. 2004;22(14S):519. Reference Source
99. Smith IE Dowsett M Ebbs SR: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23(22):5108-5116. 15998903 10.1200/JCO.2005.04.005
100. Baselga J Semiglazov V van Dam P: Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27(16):2630-2637. 19380449 10.1200/JCO.2008.18.8391
101. Sataloff DM Mason BA Prestipino AJ: Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 1995;180(3):297-306. 7874340
102. Fisher B Bryant J Wolmark N: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8):2672-2685. 9704717
103. Bear H: Primary chemotherapy for operable breast cancer: the NSABP experience. Breast Cancer Research. 2005;7(Suppl 1):S17. 10.1186/bcr1221
104. Bear HD Anderson S Brown A: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21(22):4165-4174. 14559892 10.1200/JCO.2003.12.005
105. Loibl S von Minckwitz G Raab G: Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol. 2006;13(11):1434-1442. 16983592 10.1245/s10434-006-9011-2
106. Steger EK Hausmaninger H Gnant M: 6 vs. 3 cycles of epirubicin/docetaxel + G-CSF in operable breast cancer: results of ABCSG-14.Steger, et al.22 (14 Supplement): 553 -- ASCO Meeting Abstracts. J Clin Oncol. 2004;22(suppl 553). Reference Source
107. Guarneri V Frassoldati A Bottini A: Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol. 2012;30(16):1989-1995. 22493419 10.1200/JCO.2011.39.0823
108. Untch M Fasching PA Konecny GE: Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011;29(25):3351-3357. 21788566 10.1200/JCO.2010.31.4930
109. Robidoux A Tang G Rastogi P: Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14(12):1183-1192. 24095300 10.1016/S1470-2045(13)70411-X
110. Keating GM: Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer. Drugs 2012;72(3):353-360. 22316351 10.2165/11209000-000000000-00000
111. Gianni L Pienkowski T Im YH: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32. 22153890 10.1016/S1470-2045(11)70336-9
112. Schneeweiss A Chia S Hickish T: Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278-2284. 23704196 10.1093/annonc/mdt182
113. Yao S: FDA approves Perjeta for neoadjuvant breast cancer treatment.2013. Reference Source
114. Liu M Mo QG Wei CY: Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis. Oncol Lett. 2013;5(3):983-991. 23426861 10.3892/ol.2012.1093 3576281
115. Rugo HS Olopade O DeMichele A: Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY2 trial. Canc Res. 2013;72(Suppl). Reference Source